Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -11.85% is 125% below its 3-year average of 47.36%, near the low end of its 3-year range (-11.85%–170.56%).
As of the fiscal period ended Tuesday, March 31, 2026. 91.28% below its 12-month average of -6.20%.
Annual fiscal-year return on equity; no daily interpolation. Historical series through 2026-03-31.
RETURN ON EQUITY (ROE)
-11.85%
RETURN ON EQUITY (ROE) AVG TTM
-6.20%
RETURN ON EQUITY (ROE) AVG 3Y
47.36%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-91.28%
CURRENT VS 3Y AVG
-125.02%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+71.79%
vs the sector median at left
Cellyan Biotechnology Co., Ltd
Market Cap
$1.13M
Return on Equity (ROE)
-11.85%
TTM Avg
-6.20%
3Y Avg
47.36%
5Y Avg
N/A
Market Cap
$1.12M
Return on Equity (ROE)
-200.63%
TTM Avg
-312.18%
3Y Avg
-122.70%
5Y Avg
-56.14%
Market Cap
$1.17M
Return on Equity (ROE)
N/A
TTM Avg
558.67%
3Y Avg
54.46%
5Y Avg
-8.27%
Market Cap
$1.08M
Return on Equity (ROE)
-57.87%
TTM Avg
-222.45%
3Y Avg
-164.72%
5Y Avg
-135.78%
Market Cap
$1.01M
Return on Equity (ROE)
-93.97%
TTM Avg
234.49%
3Y Avg
123.23%
5Y Avg
1171.22%
Market Cap
$946332.00
Return on Equity (ROE)
-21.18%
TTM Avg
-23.90%
3Y Avg
-48.17%
5Y Avg
-962.79%
Market Cap
$1.32M
Return on Equity (ROE)
-111.51%
TTM Avg
-753.43%
3Y Avg
-507.39%
5Y Avg
-356.28%
Market Cap
$1.33M
Return on Equity (ROE)
-114.48%
TTM Avg
-127.66%
3Y Avg
-155.08%
5Y Avg
-465.16%
Market Cap
$1.34M
Return on Equity (ROE)
-253.57%
TTM Avg
334.28%
3Y Avg
134.39%
5Y Avg
95.16%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cellyan Biotechnology Co., Ltd (HKPD) | $1.13M | -11.85% | -6.20% | 47.36% | N/A |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.12M | -200.63% | -312.18% | -122.70% | -56.14% |
| IM Cannabis Corp. (IMCC)vs › | $1.17M | N/A | 558.67% | 54.46% | -8.27% |
| Clearmind Medicine Inc. (CMND)vs › | $1.08M | -57.87% | -222.45% | -164.72% | -135.78% |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.01M | -93.97% | 234.49% | 123.23% | 1171.22% |
| Sunshine Biopharma, Inc. (SBFM)vs › | $946332.00 | -21.18% | -23.90% | -48.17% | -962.79% |
| Genprex, Inc. (GNPX)vs › | $1.32M | -111.51% | -753.43% | -507.39% | -356.28% |
| NewcelX Ltd. (NCEL)vs › | $1.33M | -114.48% | -127.66% | -155.08% | -465.16% |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.34M | -253.57% | 334.28% | 134.39% | 95.16% |
| GlucoTrack, Inc. (GCTK)vs › | $901902.00 | N/A | -255.88% | -273.58% | -200.54% |
ROE
-11.8%
ROA
-8.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-03-31 | -11.85% |
| 2025-03-31 | -0.54% |
| 2024-03-31 | 31.26% |
| 2023-03-31 | 170.56% |
